



04-26-02

PATENT
Attorney Docket No. 5007
Express Mail Label No. EV 010522409 U

1614
RECEIVED
MAY 02 2002
TECH CENTER 1600/2900
5-8-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re The Application of:)	
Calias et al.)	
)	Examiner: Not Yet Assigned
Serial No.: 09/784,402)	
)	
Filed: February 15, 2001)	Art Unit: 1614
)	
For: Modification of Biopolymers For)	
Improved Drug Delivery)	

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement herewith is being filed before the mailing of a first Office Action on the merits.

Applicants submit form PTO-1449 for consideration under CFR § 1.97(b) along with copies of the references listed #1-26.

Certain of the listed references were cited in the International Search Report issued in the corresponding PCT application (copy attached herewith).

Applicants believe that no fee is due with this submission.


U.S.S.N.: 09/784,402

Filed: February 15, 2001

INFORMATION DISCLOSURE STATEMENT

However, if any additional fees are required, the Commissioner is authorized to charge the said fees to Deposit Account No. 07-1074.

Respectfully submitted,



Date: April 25, 2002

Isabelle A. S. Blundell, Ph.D.
Attorney for Applicants
Registration No. 43,321

GENZYME CORPORATION
Legal Department
One Kendall Square
Cambridge, MA 02139
Tel. (617) 591-5698
Fax. (617) 252-7977

EV010522409US)